- Nineteen prisoners use cutlery to break out of cells at Winchester prison
- France wants progress in Ukraine before Russia returns to G7
- Italy president begins talks to seek way out of government crisis
- Italian PM expected to resign as political chaos deepens
- Russia says US cruise missile test ‘regrettable’
- Kremlin - No date set for Normandy talks on Ukraine despite Macron meeting
- Egypt court hands out 6 death sentences on terror charges
- Putin says Russian nuclear explosion poses no threat
- Russian panel eyes alleged foreign interference in protests
- Gran Canaria wildfire triggers evacuation of thousands of people
- PM Johnson calls on Germany and France to compromise on Brexit
- Sudan's ex-president Bashir arrives at corruption trial
TEHRAN, April 12 - Takeda Pharmaceutical (4502.T) has sounded out its major creditors for loans, two sources with direct knowledge of the matter said, as it moves closer to a bid for London-listed rare-disease specialist Shire (SHP.L) that could top $40 billion.
TEHRAN, Young Journalists Club (YJC) - Takeda Pharmaceutical (4502.T) has sounded out its major creditors for loans, two sources with direct knowledge of the matter said, as it moves closer to a bid for London-listed rare-disease specialist Shire (SHP.L) that could top $40 billion.
Expectations that Japan’s largest drugmaker by sales will bid for Shire before an April 25 deadline have mounted since its chief executive Christophe Weber discussed the strategic case for the deal at a briefing with analysts last week.
Weber said at the briefing, which was closed to the media, that Takeda was weighing a deal for all of Shire and there was scope to increase debt, according to analysts.
Takeda has sounded out creditors including its main bank Sumitomo Mitsui Banking Corp, the two sources said on Thursday, declining to be identified as the matter was confidential.
Kyodo News reported earlier that Takeda was looking for loans of several trillion yen (tens of billions of dollars) in total from multiple banks.
Shire shares have risen 17 percent to value the company at around $46 billion, or $9 billion bigger than Takeda, after the Japanese firm said on March 28 that it was considering a bid for the London-listed drugmaker.
At that valuation, a successful bid would be the largest ever overseas acquisition by a Japanese company and propel Takeda, helmed by Frenchman Weber, into the top ranks of global drugmakers.
Source:Reuters
Your Comment